Sugi Predict

Sugi Predict / Targets / LTK

LTK

Leukocyte tyrosine kinase receptor · P29376 · LTK on Sugi Atlas →

77,776 patent compounds predicted against LTK, 58,226 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL98881 SCHEMBL98881 0.57 3/20
SCHEMBL100736 SCHEMBL100736 0.50 3/20
SCHEMBL100040 SCHEMBL100040 0.48 3/20
SCHEMBL100903 SCHEMBL100903 0.47 3/20
SCHEMBL101889 SCHEMBL101889 0.46 3/20
SCHEMBL101518 SCHEMBL101518 0.45 3/20
SCHEMBL99210 SCHEMBL99210 0.43 3/20
SCHEMBL101240 SCHEMBL101240 0.41 3/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 2/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL99225) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL101279) 1.00 2/20
SCHEMBL99245 SCHEMBL99245 0.98 2/20
SCHEMBL99371 SCHEMBL99371 0.98 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
Ruxolitinib Ruxolitinib (SCHEMBL99771) 0.84 2/20
Ruxolitinib Ruxolitinib (SCHEMBL100078) 0.84 2/20
SCHEMBL101345 SCHEMBL101345 0.82 2/20

Clinical trials — most relevant to LTK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. PHASE1/PHASE2UNKNOWN
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation PHASE2COMPLETED
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia PHASE2RECRUITING
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors PHASE2NOT_YET_RECRUITING
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL PHASE2ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria PHASE1COMPLETED
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL PHASE1COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment nanCOMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia nanUNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Innate T Cells and TKI Discontinuation nanACTIVE_NOT_RECRUITING
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LTK binder may also engage these)

ProteinNameSimilarity
P08923 — 1.000 P08923 →
AXL Tyrosine-protein kinase receptor UFO 0.981 landscape →
Q00993 — 0.980 Q00993 →
PKN3 Serine/threonine-protein kinase N3 0.975 landscape →
Q8K045 — 0.974 Q8K045 →
FGFR4 Fibroblast growth factor receptor 4 0.973 landscape →
Q9WTM3 — 0.973 Q9WTM3 →
Q13444 — 0.972 Q13444 →
B2RYG7 — 0.972 B2RYG7 →
P60882 — 0.972 P60882 →
P55146 — 0.972 P55146 →
TYRO3 Tyrosine-protein kinase receptor TYRO3 0.972 landscape →
Q93038 — 0.971 Q93038 →
Q2TA57 — 0.971 Q2TA57 →
Q9WTL3 — 0.970 Q9WTL3 →
Q05BQ1 — 0.970 Q05BQ1 →
Q96PE1 — 0.970 Q96PE1 →
Q9HBX8 — 0.970 Q9HBX8 →
Q8NAG6 — 0.970 Q8NAG6 →
Q13683 — 0.969 Q13683 →
Q6PRD1 — 0.969 Q6PRD1 →
Q8VCM2 — 0.969 Q8VCM2 →
P35739 — 0.969 P35739 →
Q9JLG8 — 0.969 Q9JLG8 →
O75888 — 0.969 O75888 →
Q8BNJ2 — 0.969 Q8BNJ2 →
Q91ZT7 — 0.968 Q91ZT7 →
Q5RFQ8 — 0.968 Q5RFQ8 →
Q3UFB7 — 0.968 Q3UFB7 →
Q27977 — 0.968 Q27977 →